Effect of docosahexaenoic acid monoacylglyceride on systemic hypertension and cardiovascular dysfunction

Am J Physiol Heart Circ Physiol. 2015 Jul 1;309(1):H93-H102. doi: 10.1152/ajpheart.00823.2014. Epub 2015 Apr 24.

Abstract

ω-3 Fatty acid supplementation has been associated with lower blood pressure. Cardiovascular diseases are also known to be linked directly to an increase in ω-6 and a reduction in ω-3 fatty acid levels in blood circulation and tissues. To determine the effect of docosahexaenoic acid monoglycerides (MAG-DHA) on blood pressure, lipid profiles, and vascular remodeling in rats fed a high-fat/high-carbohydrate (HFHC) diet. Studies were performed in male rats subjected to 8 wk of HFHC diet supplemented or not with 3 g/day MAG-DHA. After 8 wk of daily MAG-DHA treatment, rats in the HFHC + MAG-DHA group had lower arterial blood pressure and heart rate compared with the HFHC group. Moreover, MAG-DHA prevented the increase aortic wall thickness, whereas lipid analysis of aortic tissues revealed an increase in DHA/AA ratio correlated with the production of resolvin D2 and D3 metabolites. Histological analysis revealed that MAG-DHA prevented the development of LVH in the HFHC group. Serum lipid profile analysis further showed a decrease in total cholesterol (TC) and LDL, including very low-density lipoprotein (VLDL) and triglyceride (TG) levels, together with an increase in HDL levels after 8 wk of MAG-DHA treatment compared with the HFHC group. Furthermore, daily MAG-DHA treatment resulted in reduced proinflammatory marker levels such as CRP, IL-6, TNFα, and IL-1β. Altogether, these findings revealed that per os administration of MAG-DHA prevents HFHC-diet induced hypertension and LVH in rats.

Keywords: cardiac hypertrophy; docosahexaenoic acid; hypertension; inflammation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aorta / drug effects*
  • Aorta / pathology
  • Blood Pressure / drug effects*
  • C-Reactive Protein / drug effects
  • C-Reactive Protein / metabolism
  • Cholesterol, HDL / drug effects
  • Cholesterol, HDL / metabolism
  • Cholesterol, LDL / drug effects
  • Cholesterol, LDL / metabolism
  • Cholesterol, VLDL / drug effects
  • Cholesterol, VLDL / metabolism
  • Diet, High-Fat
  • Fatty Acids, Omega-3 / pharmacology
  • Heart Ventricles / drug effects*
  • Heart Ventricles / pathology
  • Hypertension*
  • Hypertrophy, Left Ventricular / pathology
  • Interleukin-1beta / drug effects
  • Interleukin-1beta / metabolism
  • Interleukin-6 / metabolism
  • Monoglycerides / pharmacology*
  • Rats
  • Triglycerides / metabolism
  • Tumor Necrosis Factor-alpha / drug effects
  • Tumor Necrosis Factor-alpha / metabolism
  • Vascular Remodeling / drug effects*

Substances

  • Cholesterol, HDL
  • Cholesterol, LDL
  • Cholesterol, VLDL
  • Fatty Acids, Omega-3
  • IL1B protein, rat
  • Interleukin-1beta
  • Interleukin-6
  • Monoglycerides
  • Triglycerides
  • Tumor Necrosis Factor-alpha
  • docosahexaenoic acid monoacylglyceride
  • C-Reactive Protein